Neuroscience
AAN Presentation 2019: Update from SUNFISH part 1: Safety, tolerability and PK/PD from the dose-finding study, including exploratory efficacy data in patients with Type 2 or 3 spinal muscular atrophy (SMA) treated with risdiplam (RG7916)
May 07, 2019
by [E Mercuri, G Baranello, J Kirschner, L Servais, N Goemans, MC Pera, M Tichy, WY Yeung, H Kletzl, M Gerber, C Czech, Y Cleary, K Gorni and O Khwaja]
SUNFISH (NCT02908685) is a multicenter, two-part, randomized, placebo-controlled, double-blind Phase 2 study evaluating the efficacy and safety of risdiplam (RG7916) in patients with Type 2 or Type 3 SMA aged 2-25 years. This presentation describes safety, tolerability and PK/PD data from all patients in SUNFISH Part 1 and exploratory efficacy data in patients treated with risidplam for ≥1 year.
Enter the password to open this PDF file:
File name:
-
File size:
-
Title:
-
Author:
-
Subject:
-
Keywords:
-
Creation Date:
-
Modification Date:
-
Creator:
-
PDF Producer:
-
PDF Version:
-
Page Count:
-
Preparing document for printing…
0%
Receive this presentation and more content via email
Related Content
-
Also In Spinal Muscular Atrophy:
AAN Presentation 2019: FIREFISH Part 1: Survival, ventilation and swallowing ability in infants with Type 1 SMA receiving risdiplam (RG7916)
-
Also In Spinal Muscular Atrophy:
AAN Presentation 2019: Update from SUNFISH part 1: Safety, tolerability and PK/PD from the dose-finding study, including exploratory efficacy data in patients with Type 2 or 3 spinal muscular atrophy (SMA) treated with risdiplam (RG7916)
-
Also In Spinal Muscular Atrophy:
AAN Presentation 2019: FIREFISH Part 1: 1-year results on motor function in infants with Type 1 SMA